NEW YORK (GenomeWeb News) – Fluidigm today said it has closed on its public offering of 4,209,000 shares of its common stock and raised $56.1 million in net proceeds.

The South San Francisco, Calif.-based firm announced the offering last week and priced its shares at $14.25. It plans to use proceeds for R&D, commercialization efforts, working capital, and other general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.